SLC5A2 and type 2 diabetes mellitus: It is important to note that the nephroprotective mechanism related to the reduction in albuminuria of SGLT-2 inhibitors in patients with T2DM and ACKD is explained more by the synergistic effect of an RAAS blockade on efferent glomerular arterioles to reduce intraglomerular pressure than by the rebalancing of tubule glomerular feedback, which induces the vasoconstriction of the afferent arteriole and thus reduces glomerular hyperfiltration.